Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.

被引:69
作者
Guthery, SL
Heubi, JE
Bucuvalas, JC
Gross, TG
Ryckman, FC
Alonso, MH
Balistreri, WF
Hornung, RW
机构
[1] Cincinnati Childrens Hosp, Med Ctr, Pediat Liver Care Ctr, Cincinnati, OH USA
[2] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Hematol & Oncol, Cincinnati, OH USA
[3] Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA
关键词
D O I
10.1097/01.TP.0000057244.03192.BD
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Previous studies have suggested an increased risk of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) in patients receiving tacrolimus for immunosuppression. We hypothesized that after correction for confounding variables, immunosuppression with tacrolimus is not associated with an increased risk of EBV-PTLD. Methods. Potential cases of EBV-PTLD, identified by chart review, were independently ascertained by three clinicians and defined using published criteria. Agreement in diagnosing EBV-PTLD was measured using Kappa coefficients. Unadjusted and adjusted relative risk estimates were determined using proportional hazards regression. Results. Twenty-three cases of EBV-PTLD were identified in 221 patients, a proportion of 10.4% (95% confidence interval [CI]: 6.4%-14.4%). Multivariable analysis revealed that immunosuppression with tacrolimus was associated with an increased risk of EBV-PTLD (relative risk 3.10:95% Cl: 1.21-7.92), as was age at transplantation as a continuous variable (parameter estimate -0.15, P=0.03). Kappa coefficients in diagnosing EBV-PTLD and subclassifying as neoplastic and non-neoplastic EBV-PTLD were 0.73 (95% Cl: 0.54-0.93) and 0.54 (95% Cl: 0.40-0.68), respectively. Patients with neoplastic PTLD demonstrated a lower probability of survival than patients with non-neoplastic PTLD and non-cases. Conclusions. Immunosuppression with tacrolimus and young age at transplantation are associated with an increased risk of EBV-PTLD in children undergoing liver transplantation, although we cannot exclude detection bias as an explanation for this observed increase. Good agreement between observers can be achieved using previously published criteria for defining EBV-PTLD. Patients with neoplastic EBV-PTLD may have a worse prognosis, and thus identification of risk factors for the development of this subtype of the disorder may be more important.
引用
收藏
页码:987 / 993
页数:7
相关论文
共 18 条
[1]  
BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110
[2]   Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients [J].
Cacciarelli, TV ;
Reyes, J ;
Jaffe, R ;
Mazariegos, GV ;
Jain, A ;
Fung, JJ ;
Green, M .
PEDIATRIC TRANSPLANTATION, 2001, 5 (05) :359-364
[3]  
Chang K L, 1992, Diagn Mol Pathol, V1, P246, DOI 10.1097/00019606-199203000-00037
[4]  
COX KL, 1995, TRANSPLANTATION, V59, P524
[5]   Lymphoproliferative disorders after organ transplantation in children [J].
Dror, Y ;
Greenberg, M ;
Taylor, G ;
Superina, R ;
Hébert, D ;
West, L ;
Connolly, B ;
Sena, L ;
Allen, U ;
Weitzman, S .
TRANSPLANTATION, 1999, 67 (07) :990-998
[6]  
JAIN A, 2001, AM J TRANSPLANT, V1, pA235
[7]   MEASUREMENT OF OBSERVER AGREEMENT FOR CATEGORICAL DATA [J].
LANDIS, JR ;
KOCH, GG .
BIOMETRICS, 1977, 33 (01) :159-174
[8]   Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population [J].
Molmenti, EP ;
Wilkinson, K ;
Molmenti, H ;
Roden, JS ;
Squires, RH ;
Fasola, CG ;
Tomlinson, G ;
Nagata, DE ;
D'Amico, L ;
Lopez, MJ ;
Savino, LM ;
Marubashi, S ;
Sanchez, EQ ;
Goldstein, RM ;
Levy, MF ;
Andrews, W ;
Andersen, JA ;
Klintmalm, GB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (06) :535-538
[9]  
NEUHAUS P, 1994, LANCET, V344, P423
[10]   Posttransplant lymphoproliferative disease in pediatric liver transplantation - Interplay between primary Epstein-Barr virus infection and immunosuppresion [J].
Newell, KA ;
Alonso, EM ;
Whitington, PF ;
Bruce, DS ;
Millis, JM ;
Piper, JB ;
Woodle, ES ;
Kelly, SM ;
Koeppen, H ;
Hart, J ;
Rubin, CM ;
Thistlethwaite, JR .
TRANSPLANTATION, 1996, 62 (03) :370-375